3 results
Approved WMOCompleted
To evaluate the feasibility of 89Zr-bevacizumab-PET imaging as predictive biomarker before and during treatment with everolimus in patients with neuroendocrine tumors.
Approved WMOCompleted
Primary• To compare the anticholinergic side effects between repeated intravaginal administration of oxybutynin with the vaginal MedRing device and repeated oral administrationSecondary• To explore the pharmacokinetics of oxybutynin and its main…
Approved WMOCompleted
To assess the anti-tumor activity of LGX818/MEK162 in combination with third targeted agents after progression on LGX818/MEK162 combination therapy.